Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.59 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876341 | 0.88 | KDM4E (0.76) | KDM4EKMT2AMEN1MCHR1CHRM1 | |
| SCHEMBL1543277 | 0.87 | MCHR1 (0.77) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL6705751 | 0.85 | MCHR1 (0.65) | KDM4EMCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL2926587 | 0.80 | MCHR1 (0.84) | KDM4EKMT2AMCHR1SMN1; SMN2RAB9A | |
| SCHEMBL2926947 | 0.80 | MCHR1 (0.82) | KDM4EKMT2AMCHR1SMN1; SMN2RAB9A | |
| SCHEMBL6224669 | 0.77 | MCHR1 (0.71) | KDM4EMCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL3867744 | 0.77 | NPC1 (0.67) | KDM4EKMT2AMEN1MCHR1CHRM1 | |
| SCHEMBL5645871 | 0.76 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL3875743 | 0.76 | MCHR1 (0.80) | KDM4EMCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL6705708 | 0.76 | MCHR1 (0.61) | KDM4EKMT2AMEN1MCHR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | claimed |
| JP-2011524894-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2307378-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | claimed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | claimed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2307378-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009153721-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128690-A1 | Amine derivative | MC1R, MC2R, MC4R | KDM4E 1415/4885KMT2A 1130/4885MEN1 298/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | KDM4E 3753/4885KMT2A 3206/4885MEN1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.